| NCT ID | NCT06379698 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Tumoral Kidney |
| Study Type | INTERVENTIONAL |
| Enrollment | 39 participants |
| Start Date | 2024-05-28 |
| Primary Completion | 2027-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 39 participants in total. It began in 2024-05-28 with a primary completion date of 2027-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare preoperative information and patient experience using a personalized versus a generic 3D printed models of patients' tumoral kidney before and after nephron-sparing surgery. The main outcome measure will be based on semi-structured interviews with the patient and the carers.
Eligibility Criteria
Inclusion Criteria: Patients: * Adult patients (≥ 18 years of age) * Scheduled for surgical management by laparoscopic robotic-assisted partial nephrectomy (1st management for a unilateral or bilateral kidney tumor) * Expressed consent for integration in the UroCCR database * Expressed consent for participation in the Rein-3D Personalize study * Patients affiliated or benefiting from social security system Professionals: * Professionals working with patients treated in the Urology, Andrology and Renal Transplant - Department of the Bordeaux University Hospital for at least two months prior to the implementation of 3D models * Free, informed and signed consent Exclusion Criteria: Patients * Metastatic at inclusion * Previous renal cancer(s) * Single kidney at time of inclusion * No preoperative CT scan, or poor-quality CT scan unable to provide reliable 3D modeling * Person under legal protection (safeguard of justice, guardianship or curatorship) * Difficulty understanding and expressing oneself in French Professionals * Professionals on internship lasting less than 6 months * Professionals with no contact with patients
Contact & Investigator
Gaëlle MARGUE, Docteur
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT06379698 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tumoral Kidney. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06379698 currently recruiting?
Yes, NCT06379698 is actively recruiting participants. Contact the research team at gaelle.margue@chu-bordeaux.fr for enrollment information.
Where is the NCT06379698 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06379698 clinical trial?
NCT06379698 is sponsored by University Hospital, Bordeaux. The principal investigator is Gaëlle MARGUE, Docteur at University Hospital, Bordeaux. The trial plans to enroll 39 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.